Answers are grounded in this paper and cite their sources.
OBJECTIVE: Amitriptyline remains in use among older adults despite safety concerns. This diagnosis-independent systematic review and meta-analysis evaluated amitriptyline safety and tolerability versus active comparators or placebo in older adults. DATA SOURCES: We searched MEDLINE, CENTRAL, Embase, PsycINFO, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) through September 30, 2026. STUDY SELECTION AND DATA EXTRACTION: Eligible randomized controlled trials (RCTs) compared amitriptyline with placebo or active comparators in older adults (participants aged ≥60 years or study populations with mean age ≥70 years). Primary outcomes included serious adverse events (SAEs), dizziness, and acute cognitive adverse outcomes. Secondary outcomes included 60 safety, tolerability, and acceptability outcomes. Risk ratios (RRs) and mean differences were calculated. Random-effects meta-analyses were conducted separately versus placebo and active comparators on an intention-to-treat basis. Subgroup and sensitivity analyses explored robustness. DATA SYNTHESIS: In total, 32 RCTs (2243 participants) were included. Versus active comparators, that is, antidepressants or mood stabilizers, amitriptyline did not increase serious adverse events (SAEs) (RR = 1.13; 95% CI, 0.66-1.93), but increased dizziness (RR = 1.38; 95% CI, 1.06-1.79). Regarding cognition, no difference was found for disturbance in attention (RR = 2.44; 95% CI, 0.89-6.71) or confusional state (RR = 1.76; 95% CI, 0.42-7.35); disorientation was reported in 1 trial. Amitriptyline was associated with increased risk of any adverse event, withdrawals due to adverse events, anticholinergic and sedative adverse events, and weight gain. Placebo-controlled data were sparse, with no SAEs reported. Limitations included short trials, sparse adverse event reporting, and restricted eligibility. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Amitriptyline's main limitation in older adults may be tolerability rather than excess serious harm. It should not be a first-line option, but may remain reasonable for selected patients with clear therapeutic rationale. CONCLUSION: Compared with active comparators, amitriptyline showed no detectable excess in SAEs but increased dizziness and anticholinergic and sedative adverse events.
No takes yet. Share an insight, caveat, or question.
Parisis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: